"Science Corporation is embarking on human trials for a biohybrid brain-computer interface, aiming to combine lab-grown neurons with electronics. Dr. Murat Günel will lead these efforts, focusing on the surgical placement of the first sensor into a patient's brain."
"The company’s most advanced product, PRIMA, is designed to restore vision in individuals suffering from blindness due to macular degeneration. Following its acquisition in 2024, PRIMA has progressed through clinical trials, with plans for wider availability in Europe pending regulatory approval."
"Max Hodak's vision extends beyond treating diseases; he aims to create communication links between computers and the human brain, potentially enhancing human capabilities by adding new senses. His career has been dedicated to this goal, from his early experiences in neuroscience to co-founding Neuralink."
"Despite advancements in brain-computer interfaces, including devices that allow ALS patients to control computers through thought, the market remains uncertain due to regulatory challenges and the limited number of patients who could benefit from such technologies."
Science Corporation, founded by Max Hodak, is initiating US human trials for a biohybrid brain-computer interface, led by neurobiologist Dr. Murat Günel. The company aims to integrate lab-grown neurons with electronics. Its flagship product, PRIMA, aims to restore vision for those with blindness. Following a $230 million Series C funding round, Science is valued at $1.5 billion. Hodak envisions enhancing human capabilities through reliable brain-computer communication, despite regulatory hurdles and a limited patient market for existing devices.
Read at TechCrunch
Unable to calculate read time
Collection
[
|
...
]